End the Grey Zone: Why Mexico Must Regulate Cannabis Now

In business, nothing is more expensive than uncertainty. Those of us leading companies in highly complex sectors, such as cannabis, know that a market in the shadows only exacerbates speculation, contraband, and illegal imports. On the other hand, the extreme of an over-regulated market yields benefits solely for massive international capital, fostering a broad grey market. True value and maturity are achieved when social benefit-centered regulation aligns with the market's capacity to expand under the protection of the law.

Over the past three months, we have witnessed a global tectonic shift. The realignment of pieces in North America — highlighted by the formal progress of the DEA’s rescheduling to Schedule III in the United States to exempt the medical sector from the suffocating 280E tax code — combined with strict new cross-border tariff measures on supply chains in Canada, is sending an unequivocal signal to international markets: the cannabis "grey market" is formally coming to an end.

Stock market speculation, companies exploiting legal loopholes in synthetic cannabinoids—and their resulting impact on the grey market—deficient production processes, and homemade formulas will all be displaced by science, rigorous pharmaceutical standards, traceability technology, and, above all, mandatory regulatory compliance to remain competitive in international trade.

The global cannabis industry no longer competes over who achieves higher sales or devises the most daring cannabinoid blend; it must now demonstrate which company is most financially viable, which organization possesses the most robust and reliable supply chain, and who holds the most advanced, safe transformation, production, and packaging processes. On a personal level, this is a source of pride: since its founding, HempMeds has been a pioneer in establishing these exact operational protocols to guarantee product quality, from hemp cultivation all the way to the hands of those who benefit from CBD from a trusted source.

However, a macro analysis of the new challenges facing the industry brings us back to the perpetual question: Will Mexico once again become a pioneer in this sector—as it was in 2017 when it became one of the first countries to legally recognize the therapeutic and industrial potential of cannabis and its derivatives—or will it remain stuck in its current state, paralyzed by a framework that is nearly impossible to implement due to a lack of standardization with international regulations?

The Trap of 'Paper-Only' Legalization

In mid-2026, the Mexican reality borders on bureaucratic surrealism. While COFEPRIS repeatedly complies with Supreme Court rulings and jurisprudence to grant personal consumption and possession permits, the country remains trapped in a flagrant legislative paralysis.

We continue to operate under a schizophrenic scheme:

• A constitutional framework that recognizes the free development of personality.
• Health legislation that acknowledges the scientific and medical uses of cannabis yet remains unenforceable due to the absence of clear secondary regulations.
• A health authority issuing individual licenses at a trickle, exclusively by judicial mandate.
• A complete absence of a formal, taxable, and regulated commercial market for cultivation, processing, and industrial-scale distribution.

To make matters worse, we stand at the threshold of the USMCA (T-MEC) agreement review, where discussions regarding security, federal taxes, and agricultural raw-material trade will inevitably take center stage. Yet in Mexico, we have still failed to engage in a substantive debate to standardize our cannabis regulatory framework alongside our northern partners.

Mexico’s Role in 2026

In less than a decade, Mexico went from being one of the markets with the highest industry potential—with financial projections exceeding $1 billion USD—to a state of complete standstill. And no, this is not just about opening retail shops on every corner; as a CEO in this industry, I view it through the lens of economic competitiveness. The lack of a clear secondary commercial regulation costs the country on three critical fronts:

1. Sovereignty and Commercial Borders: While Canada and the U.S. refine their export models, Mexico—blessed with the continent's finest climatic, agricultural, and logistical cost advantages—remains a passive spectator and an importer of high-value-added processed derivatives.
2. Legal Certainty for Investment: Private equity funds do not invest in "court-injunction criteria"; they invest in clear secondary laws, defined tariff codes, and stable rules of the game. The gap left by Mexico is currently being captured by markets in Europe (such as Switzerland’s accelerated commercial model) and South America.
3. Tax Revenue and Social Impact: Instead of directing tax revenue from a multi-billion-dollar industry toward public health and the development of the Mexican countryside, cash flows continue to fuel informality and legal insecurity.

The Core Question

The end of the global "grey zone" demonstrates that cannabis is no longer a social experiment, but a mature Fast-Moving Consumer Goods (FMCG) category, a precision medicine field, and a cornerstone of agro-industrial development.

Mexico cannot continue pretending that regulation can be solved through the clerk windows of the Judicial Branch. The question of "When?" should no longer be directed at judges, but at lawmakers and state economic policy strategists.

If Mexico does not take the reins of its own market this year, the international environment will inevitably define it for us, leaving us—once again—as mere low-cost manufacturers of an opportunity that was ours to lead.

Today, more than ever, it is vital to reinforce the collaborative stance that HempMeds has maintained across all operating markets: building bridges of dialogue, sharing insights on international regulatory successes and failures, and, above all, leveraging the scientific evidence gathered over the last decade, particularly that generated by Mexican researchers. All of this with a single goal: for Mexico to reclaim its leadership position in an industry that has deeply transformed society through therapeutic and industrial cannabis applications.